1/3
Vocabulary review covering gemfibrozil's inhibition of CYP2C8 and its specific pharmacokinetic interactions with pioglitazone and repaglinide.
Gemfibrozil
A drug that inhibits CYP2C8, leading to increased levels of medications cleared by that enzyme.
CYP2C8
The metabolic enzyme inhibited by gemfibrozil that is responsible for clearing medications such as pioglitazone and repaglinide.
Gemfibrozil and Pioglitazone Interaction
An interaction where gemfibrozil raises pioglitazone levels, resulting in an increased risk of edema and heart failure (HF), as well as increased hypoglycemia with other agents; the label specifies limiting pioglitazone to 15mg/day.
Gemfibrozil and Repaglinide Interaction
An interaction where gemfibrozil markedly increases repaglinide levels, causing severe and prolonged hypoglycemia; the textbook notes to use with caution, while the drug label states it is contraindicated.